The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma.
Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma. For each condition, using octreotide was associated with doubled survival time. Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.
W H
WH
Schonfeld
E P
EP
Eikin
E A
EA
Woltering
I M
IM
Modlin
L
L
Anthony
K F
KF
Villa
M
M
Zagari
D018931:Antineoplastic Agents, Hormonal / Q000191:economics* / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004180:Direct Service Costs / Q000706:statistics & numerical data; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D018803:Models, Economic; D015282:Octreotide / Q000191:economics* / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000191:economics*; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires; D003969:Vipoma / Q000188:drug therapy / Q000191:economics*
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide